BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical introduced the results from an aggregated data analysis at the Vascular Interventional Advances (VIVA) conference, highlighting the Zilver ® PTX ® Drug ...

The FDA today approved Cook Medical's Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal ...

Treating superficial femoral artery (SFA) disease remains challenging. Bypass surgery is associated with higher morbidity rates than endovascular therapies, such as percutaneous transluminal ...

Zilver PTX stenting would be superior to PTA alone in the treatment of patients with symptomatic femoropopliteal disease. Patients were randomized in a 1:1 fashion to either Zilver PTX stent or PTA.

February 20, 2019—A correction to the 5-year data publication from Cook Medical's Zilver PTX randomized trial was issued in Circulation (2019;139:e42), revising a key figure and the stated mortality ...

LAS VEGAS--(BUSINESS WIRE)--Three-year data from the Zilver ® PTX ® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical demonstrate 70.7 percent ...

Arguably the fastest-moving topic in interventional cardiology now isn't in the coronaries but the periphery, as paclitaxel-delivering devices for femoropopliteal disease appear to lose a bit more ...

Add articles to your saved list and come back to them any time. "Will there be fish tanks?" asks one of the kids. "Will there be air-conditioning?" asks one of the blokes. "Can you book?" asks one of ...